What are the details of our trial?

If you have been told you have Favourable intermediate-risk (FIR) prostate cancer, you are not alone. FIR prostate cancer is the most commonly diagnosed type of prostate cancer. It is often treated radically (surgically removed or radiated), but also has a lower risk of metastasis or death without treatment.

We want to provide you with more information for your treatment decisions. Specifically, we are conducting a ten-year trial to see how genomic testing helps inform your treatment decisions, especially whether you are more likely to safely and confidently choose active surveillance.

What will participants do?

One group will receive three genomic tests and then be told if they are at low or high risk for cancer progression. Members of this group will then make a treatment pathway decision with their care provider. The other group will continue to receive their usual care from their doctor and make their treatment decision without the genomic tests.

Members in both groups will be asked to participate in surveys about their prostate cancer experience. These will occur 6 and 12 months after the start of the study. Then, every year for up to 10 years.

Learn more about eligibility, why you should participate, and what is involved in this study in our frequently asked questions section. A summary glossary is also provided at the bottom of the page for bolded or technical terms.

Any additional queries or expressions of interest may be made at the bottom of this page through the ‘Contact Us’ button.

*Note: the information provided on this page is specific to our trial. For more general information on your treatment options and prostate cancer, please refer to your treating clinician or the Prostate Cancer Foundation of Australia.

FAQs

Explanation of Technical Terms

What is genomic testing?

What are the three genomic tests being used? How will they work?

What is active surveillance? How is it different to radical therapy?

Specifics of the Trial

How do I know if I am eligible for this trial?

What are the benefits of participating in this trial?

What are the time commitments for this clinical trial? What happens once I make my treatment decision?

How are the participants assigned to the standard of care/genomically informed groups? Can I leave the trial if I change my mind?

Active Surveillance	Closely monitor the cancer through tests and treat it if changes warrant it.
Chromosome	DNA molecule coiled into a compact structure.
Cell	Smallest functional unit of our body. Makes up the tissues of our body and contains genetic material which informs how we are made.
Genome	All the genetic material of an organism – including all DNA and genes.
Gene	A section of the DNA that codes for a protein.
Germline cells	Reproductive cells (e.g. sperm and egg) that contain genetic information passed down generations.
Metastasis	The spread of cancer to parts of the body other than the initial site.
Radical Therapy	Different types of active treatment, like surgery or chemotherapy.
Somatic cells	Any cell of a living organism that is not a reproductive (germline) cell.